BioSpace News Archive

VG Acquisition Corp., a special purpose acquisition company sponsored by Virgin Group, announced that the date of its extraordinary general meeting of shareholders to vote on its proposed business combination with 23andMe, Inc., a leading consumer genetics and research company, will be June 10, 2021.

International award will fund preclinical study of CNM-Au8 nanocatalysis for the improvement of human health and lifespan in the contexts of aging and Alzheimer’s disease

Landos Biopharma, Inc and LianBio announced an exclusive collaboration and license agreement for the development and commercialization of omilancor and NX-13 in Greater China and select Asian markets.

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced financial results for the three months ending March 31, 2021 and provided a corporate update.

Algernon Pharmaceuticals Inc. announces it has received positive feedback from the U.S. Food and Drug Administration regarding its plans to investigate AP-188, a known psychedelic compound that is part of the tryptamine family, as an adjunct to physical therapy in the rehabilitation of stroke.

Milestone Pharmaceuticals Inc. announced an exclusive license and collaboration agreement with Ji Xing Pharmaceuticals to develop and, if approved, commercialize the investigational drug etripamil in patients with paroxysmal supraventricular tachycardia and additional cardiovascular conditions in Greater China.

Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, announced four scientific poster presentations featuring data for XIFAXAN®, TRULANCE® and PLENVU® to be shared at Digestive Disease Week® 2021, which takes place virtually May 21-23, 2021.

Milestone Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, reported financial results for the first quarter ended March 31, 2021 and provided a clinical, regulatory, and corporate update.

Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, announced that company management will participate in two upcoming investor conferences

New Appointments Bring Expertise and Proven Leadership to Support Asset-Centric R&D Model and Portfolio Advancement